17.96
-0.74 (-3.96%)
| Previous Close | 18.70 |
| Open | 18.34 |
| Volume | 179,661 |
| Avg. Volume (3M) | 212,733 |
| Market Cap | 2,383,055,616 |
| Price / Earnings (Forward) | 454.55 |
| Price / Sales | 119.53 |
| Price / Book | 4.03 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2026 |
| Operating Margin (TTM) | -633.21% |
| Diluted EPS (TTM) | -1.24 |
| Quarterly Revenue Growth (YOY) | -6.80% |
| Total Debt/Equity (MRQ) | 27.34% |
| Current Ratio (MRQ) | 0.960 |
| Operating Cash Flow (TTM) | -42.54 M |
| Levered Free Cash Flow (TTM) | -13.46 M |
| Return on Assets (TTM) | -4.85% |
| Return on Equity (TTM) | -21.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Mesoblast Limited | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -3.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -0.88 |
|
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.06% |
| % Held by Institutions | 3.10% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Arax Advisory Partners | 30 Sep 2025 | 200,079 |
| Summit X, Llc | 30 Jun 2025 | 199,295 |
| Penbrook Management Llc | 31 Dec 2025 | 87,575 |
| Prosperity Wealth Management, Inc. | 30 Sep 2025 | 49,950 |
| Rockbridge Investment Management, Lcc | 30 Sep 2025 | 49,150 |
| Rialto Wealth Management, Llc | 31 Dec 2025 | 46,500 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |